The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years

2007351 citationsJournal Article

Authors

Mark Nelson · Chelsea and Westminster Hospital

Christine Katlama · Pitié-Salpêtrière Hospital

Joan Montaner

David A. Cooper

Brian Gazzard

Bonaventura Clotet · Hospital Universitari Germans Trias i Pujol

Adriano Lazzarin · Vita-Salute San Raffaele University

Knud Schewe · Infektionsmedizinisches Centrum Hamburg

Abstract

The data demonstrate a favorable safety profile for tenofovir DF in the treatment of adults with HIV infection. Risk factors for development of nephrotoxicity can be identified and may be useful in managing those patients at greatest risk.

Topics & Keywords

HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions HIV Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: AIDS

Volume 21, Issue 10, pp. 1273-1281

DOI: 10.1097/qad.0b013e3280b07b33

Field-Weighted Citation Impact: 13.69